A meta-analysis of four randomized trials evaluating liver fat content (LFC) using MRI by Coelho et al.46 (2020) showed a decrease in hepatic steatosis with the use of SGLT-2 inhibitors (MD: − 3.39%, 95% CI [− 6.01, − 0.77], p = 0.01, I2 = 89%). The gene discussed is SLC5A2; the disease is fatty liver disease.